{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:50Z","timestamp":1784754950449,"version":"3.55.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32470826"],"award-info":[{"award-number":["32470826"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005088","name":"Beijing Municipal Health Commission","doi-asserted-by":"publisher","award":["2024-3-034"],"award-info":[{"award-number":["2024-3-034"]}],"id":[{"id":"10.13039\/501100005088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02412-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T17:15:28Z","timestamp":1759166128000},"page":"2881-2891","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comprehensive analysis of sparsentan-related adverse events: latest insights from VigiAccess and FAERS"],"prefix":"10.1093","volume":"38","author":[{"given":"Hongxuan","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuolin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8207-7367","authenticated-orcid":false,"given":"Boda","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2412_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2024.2319132","volume":"20","author":"H Trachtman","year":"2024","unstructured":"Trachtman H, Komers R, Inrig J (2024) Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy. Expert Rev Clin Immunol 20:571\u2013576. https:\/\/doi.org\/10.1080\/1744666X.2024.2319132","journal-title":"Expert Rev Clin Immunol"},{"key":"2412_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1042\/CS20240249","volume":"138","author":"DE Kohan","year":"2024","unstructured":"Kohan DE, Bedard PW, Jenkinson C et al (2024) Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease. Clin Sci (Lond) 138:645\u2013662. https:\/\/doi.org\/10.1042\/CS20240249","journal-title":"Clin Sci (Lond)"},{"key":"2412_CR3","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/13543784.2024.2414902","volume":"33","author":"H Nagasawa","year":"2024","unstructured":"Nagasawa H, Suzuki H, Ueda S, Suzuki Y (2024) Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy. Expert Opin Investig Drugs 33:1143\u20131152. https:\/\/doi.org\/10.1080\/13543784.2024.2414902","journal-title":"Expert Opin Investig Drugs"},{"key":"2412_CR4","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE et al (2023) Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 401:1584\u20131594. https:\/\/doi.org\/10.1016\/S0140-6736(23)00569-X","journal-title":"Lancet"},{"key":"2412_CR5","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ekir.2019.12.017","volume":"5","author":"R Komers","year":"2020","unstructured":"Komers R, Diva U, Inrig JK et al (2020) Study design of the phase 3 sparsentan versus irbesartan (DUPLEX) study in patients with focal segmental glomerulosclerosis. Kidney Int Rep 5:494\u2013502. https:\/\/doi.org\/10.1016\/j.ekir.2019.12.017","journal-title":"Kidney Int Rep"},{"key":"2412_CR6","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL et al (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet 402:2077\u20132090. https:\/\/doi.org\/10.1016\/S0140-6736(23)02302-4","journal-title":"Lancet"},{"key":"2412_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41581-023-00795-w","volume":"20","author":"M Wang","year":"2024","unstructured":"Wang M (2024) Renoprotective effects of sparsentan: clinical trial evidence in IgA nephropathy and FSGS. Nat Rev Nephrol 20:6. https:\/\/doi.org\/10.1038\/s41581-023-00795-w","journal-title":"Nat Rev Nephrol"},{"issue":"Suppl 2","key":"2412_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/nep.14340","volume":"29","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Zhang H (2024) Current understanding and new insights in the treatment of IgA nephropathy. Nephrology (Carlton) 29(Suppl 2):75\u201379. https:\/\/doi.org\/10.1111\/nep.14340","journal-title":"Nephrology (Carlton)"},{"key":"2412_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/IJNRD.S430377","volume":"16","author":"KN Campbell","year":"2023","unstructured":"Campbell KN, Griffin S, Trachtman H et al (2023) Practical considerations for the use of sparsentan in the treatment of patients with IgAN in clinical practice. Int J Nephrol Renovasc Dis 16:281\u2013291. https:\/\/doi.org\/10.2147\/IJNRD.S430377","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2412_CR10","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1053\/j.ajkd.2021.07.019","volume":"79","author":"S Kant","year":"2022","unstructured":"Kant S, Kronbichler A, Sharma P, Geetha D (2022) Advances in understanding of pathogenesis and treatment of immune-mediated kidney disease: a review. Am J Kidney Dis 79:582\u2013600. https:\/\/doi.org\/10.1053\/j.ajkd.2021.07.019","journal-title":"Am J Kidney Dis"},{"key":"2412_CR11","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000613","author":"SCW Tang","year":"2024","unstructured":"Tang SCW, Wei C, Aldworth C et al (2024) Clinical and humanistic burden of IgAN in adult patients: a global real-world survey. Kidney360. https:\/\/doi.org\/10.34067\/KID.0000000613","journal-title":"Kidney360"},{"key":"2412_CR12","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/cid\/ciz684","volume":"70","author":"NS van De Ven","year":"2020","unstructured":"van De Ven NS, Pozniak AL, Levi JA et al (2020) Analysis of pharmacovigilance databases for dolutegravir safety in pregnancy. Clin Infect Dis 70:2599\u20132606. https:\/\/doi.org\/10.1093\/cid\/ciz684","journal-title":"Clin Infect Dis"},{"key":"2412_CR13","doi-asserted-by":"publisher","first-page":"1503154","DOI":"10.3389\/fphar.2024.1503154","volume":"15","author":"Y Huang","year":"2024","unstructured":"Huang Y, Xu M, Ma X et al (2024) Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess. Front Pharmacol 15:1503154. https:\/\/doi.org\/10.3389\/fphar.2024.1503154","journal-title":"Front Pharmacol"},{"key":"2412_CR14","doi-asserted-by":"publisher","first-page":"23956","DOI":"10.1038\/s41598-021-03214-x","volume":"11","author":"D Keshishi","year":"2021","unstructured":"Keshishi D, Makunts T, Abagyan R (2021) Common osteoporosis drug associated with increased rates of depression and anxiety. Sci Rep 11:23956. https:\/\/doi.org\/10.1038\/s41598-021-03214-x","journal-title":"Sci Rep"},{"key":"2412_CR15","doi-asserted-by":"publisher","first-page":"1310286","DOI":"10.3389\/fphar.2024.1310286","volume":"15","author":"M He","year":"2024","unstructured":"He M, Yang T, Zhou J et al (2024) A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases. Front Pharmacol 15:1310286. https:\/\/doi.org\/10.3389\/fphar.2024.1310286","journal-title":"Front Pharmacol"},{"key":"2412_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13:519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2412_CR17","doi-asserted-by":"publisher","first-page":"1369384","DOI":"10.3389\/fphar.2024.1369384","volume":"15","author":"S Chen","year":"2024","unstructured":"Chen S, Fang W, Zhao L, Xu H (2024) Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database. Front Pharmacol 15:1369384. https:\/\/doi.org\/10.3389\/fphar.2024.1369384","journal-title":"Front Pharmacol"},{"key":"2412_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","volume":"346","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhou L, Shen Y et al (2024) Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database. J Affect Disord 346:223\u2013229. https:\/\/doi.org\/10.1016\/j.jad.2023.11.025","journal-title":"J Affect Disord"},{"key":"2412_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ekir.2023.11.026","volume":"9","author":"H Selvaskandan","year":"2024","unstructured":"Selvaskandan H, Barratt J, Cheung CK (2024) Novel treatment paradigms: primary IgA nephropathy. Kidney Int Rep 9:203\u2013213. https:\/\/doi.org\/10.1016\/j.ekir.2023.11.026","journal-title":"Kidney Int Rep"},{"key":"2412_CR20","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","volume":"389","author":"MN Rheault","year":"2023","unstructured":"Rheault MN, Alpers CE, Barratt J et al (2023) Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Engl J Med 389:2436\u20132445. https:\/\/doi.org\/10.1056\/NEJMoa2308550","journal-title":"N Engl J Med"},{"key":"2412_CR21","doi-asserted-by":"publisher","first-page":"CD003594","DOI":"10.1002\/14651858.CD003594.pub6","volume":"2019","author":"ID Liu","year":"2019","unstructured":"Liu ID, Willis NS, Craig JC, Hodson EM (2019) Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2019:CD003594. https:\/\/doi.org\/10.1002\/14651858.CD003594.pub6","journal-title":"Cochrane Database Syst Rev"},{"key":"2412_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.848389","volume":"9","author":"E Chavez","year":"2022","unstructured":"Chavez E, Rodriguez J, Drexler Y, Fornoni A (2022) Novel therapies for Alport syndrome. Front Med (Lausanne) 9:848389. https:\/\/doi.org\/10.3389\/fmed.2022.848389","journal-title":"Front Med (Lausanne)"},{"key":"2412_CR23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","volume":"35","author":"K El Karoui","year":"2024","unstructured":"El Karoui K, Fervenza FC, De Vriese AS (2024) Treatment of IgA nephropathy: a rapidly evolving field. J Am Soc Nephrol 35:103\u2013116. https:\/\/doi.org\/10.1681\/ASN.0000000000000242","journal-title":"J Am Soc Nephrol"},{"key":"2412_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/MNH.0000000000000979","volume":"33","author":"B Barr","year":"2024","unstructured":"Barr B, Barbour S (2024) New therapies for immunoglobulin A nephropathy: what\u2019s the standard of care in 2023? Curr Opin Nephrol Hypertens 33:311\u2013317. https:\/\/doi.org\/10.1097\/MNH.0000000000000979","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2412_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2416917","author":"Q Liang","year":"2024","unstructured":"Liang Q, Liao X, Huang Y et al (2024) Safety study on adverse events of zanubrutinib based on WHO-VigiAccess and FAERS databases. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2416917","journal-title":"Expert Opin Drug Saf"},{"key":"2412_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2412218","author":"Y Huang","year":"2024","unstructured":"Huang Y, Gao H, Lin Y et al (2024) Real-world pharmacovigilance study of FDA adverse event reporting system events for finerenone. Expert Opin Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2412218","journal-title":"Expert Opin Drug Saf"},{"key":"2412_CR27","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1177\/10600280231198925","volume":"58","author":"AW Chiu","year":"2024","unstructured":"Chiu AW, Bredenkamp N (2024) Sparsentan: a first-in-class dual endothelin and angiotensin II receptor antagonist. Ann Pharmacother 58:645\u2013656. https:\/\/doi.org\/10.1177\/10600280231198925","journal-title":"Ann Pharmacother"},{"key":"2412_CR28","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/S0140-6736(24)01168-1","volume":"404","author":"D Groothof","year":"2024","unstructured":"Groothof D, Gans ROB, Bakker SJL (2024) Sparsentan and kidney protection: improved medullary oxygenation? Lancet 404:1808. https:\/\/doi.org\/10.1016\/S0140-6736(24)01168-1","journal-title":"Lancet"},{"key":"2412_CR29","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nep.14130","volume":"28","author":"EYM Chung","year":"2023","unstructured":"Chung EYM, Badve SV, Heerspink HJL, Wong MG (2023) Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrology (Carlton) 28:97\u2013108. https:\/\/doi.org\/10.1111\/nep.14130","journal-title":"Nephrology (Carlton)"},{"key":"2412_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12882-024-03713-9","volume":"25","author":"AAA Elnaga","year":"2024","unstructured":"Elnaga AAA, Alsaied MA, Elettreby AM et al (2024) Safety and efficacy of sparsentan versus irbesartan in focal segmental glomerulosclerosis and IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. BMC Nephrol 25:316. https:\/\/doi.org\/10.1186\/s12882-024-03713-9","journal-title":"BMC Nephrol"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02412-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02412-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02412-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:46Z","timestamp":1777564786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/9\/2881\/8462669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2412"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02412-4","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}